Johnson & Johnson’s inflammatory diseases blockbuster Remicade (infliximab) faces further US competition after the FDA granted a licence for Samsung Bioepis’ biosimilar, Renflexis, in all the ...

European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...